DG DISPATCH - AACAP: Bupropion SR Effective In Treating Adult AD/HD
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - AACAP: Bupropion SR Effective In Treating Adult AD/HD

By Lara Pullen
Special to DG News

CHICAGO, IL -- October 26, 1999 -- Despite the increased recognition of adult attention deficit/hyperactivity disorder (AD/HD), there are very few placebo-controlled clinical trials addressing its pharmacotherapy. A new study indicates that bupropion SR (sustained release) results in clinically and statistically significant improvement of AD/HD in adults.

At the 46th annual meeting of the American Academy of Child and Adolescent Psychiatry, Dr. Timothy E. Wilens, of Massachusetts General Hospital, in Boston, presented the results of a randomized, double-blind, placebo-controlled trial. This trial follows an open report that suggested the usefulness of bupropion SR in adults with AD/HD.

The study comprised 40 adults (18 women/22 men) with a mean age of 38 years. Bupropion SR was initiated at 100 mg/day and titrated by 100 mg/day at weekly intervals to a target dose of 400 mg/day (200 mg twice daily).

The results show bupropion SR treatment was associated with a significant reduction in AD/HD symptoms which exceeded placebo at the end of the six-week treatment period. Seventy-six percent of subjects on bupropion SR were judged under blind conditions to have a positive response to treatment. The mean dose of bupropion SR was 362 mg/day. The bulk of improvement in AD/HD symptoms occurred after week four, suggesting either a titration effect or delayed onset of action.

Related Link: bupropion SR (sustained release).

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities